ReviewNature reviews. Cardiology2022
P2Y
2 registry-linked trialsAbstract readReview
In one paragraph
Review in Nature reviews. Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
11.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tailoring Bleeding Reduction Approaches in Patients Undergoing Percutaneous Coronary Interventions: Comparative Pharmacodynamic Effects of Potent P2Y12 Inhibitor Monotherapy Versus Dual Antiplatelet Therapy De-escalation
Comparison of ABCD-GENE Score-Guided Versus Unguided DAPT De-Escalation: A Prospective Randomized Pharmacodynamic Study in Patients Undergoing PCI The Switching Antiplatelet-9 (SWAP-9) Study
Who cites it
21 citing papers in PubMed, 70 citations in OpenAlex.
- Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity.JAMA cardiology · 2025Trial
- P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial.JAMA network open · 2024Trial
- Probabilistic Risk-Benefit Profile of Ticagrelor Monotherapy After Short Dual Antiplatelet Therapy: A Bayesian Analysis of the ULTIMATE-DAPT Trial.Clinical pharmacology and therapeutics · 2026Article
- Antiplatelet Monotherapies for Long-Term Secondary Prevention Following Percutaneous Coronary Intervention.Journal of clinical medicine · 2025Review
- One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programme.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Article
- Proteomic evaluation of the thrombosis-inflammation interplay in STEMI with MVO.BMC cardiovascular disorders · 2025Article
- Comprehensive insights into potential roles of purinergic P2 receptors on diseases: Signaling pathways involved and potential therapeutics.Journal of advanced research · 2025Review
- Current Management of Non-ST-Segment Elevation Acute Coronary Syndrome.Biomedicines · 2024Review
- Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease.European heart journal · 2024Review
- P2Y12 Receptor Inhibitor for Antiaggregant Therapies: From Molecular Pathway to Clinical Application.International journal of molecular sciences · 2024Review
- One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024Article
- Inflammation and platelet reactivity during adjunctive colchicine versus aspirin in patients with acute coronary syndrome treated with potent P2Y12 inhibitor.Frontiers in medicine · 2024Article
- Optimal anti-platelet therapy for older patients with acute coronary syndrome: a network meta-analysis of randomized trials comprising 59,284 older patients.Journal of thrombosis and thrombolysis · 2024Article
- Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.Journal of clinical medicine · 2023Review
- P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023Article
- Antioxidant Properties of Oral Antithrombotic Therapies in Atherosclerotic Disease and Atrial Fibrillation.Antioxidants (Basel, Switzerland) · 2023Review
- Individualized or Uniform De-Escalation Strategies for Antiplatelet Therapy in Acute Coronary Syndrome: A Review of Clinical Trials with Platelet Function Testing and Genetic Testing-Based Protocols.International journal of molecular sciences · 2023Review
- The conundrum of percutaneous coronary intervention without aspirin: a call for clarity.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023Article
- Aspirin should be stopped at day 0 after PCI: pros and cons.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023Article
- P2YJournal of cardiovascular development and disease · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 17 institutions in 11 countries.
Davide CapodannoCardio-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria Policlinico "Gaspare Rodolico - San Marco", University of Catania, Catania, Italy.
Usman BaberUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Deepak L BhattDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jean-Philippe ColletACTION Group, Sorbonne Université, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Institut de Cardiologie, Paris, France.
George DangasIcahn School of Medicine at Mount Sinai, Cardiovascular Institute, New York, NY, USA.
Francesco FranchiUniversity of Florida College of Medicine, Jacksonville, FL, USA.
C Michael GibsonDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4857-9125
Hyeon-Cheol GwonDepartment of Cardiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Adnan KastratiDeutsches Herzzentrum München, Cardiology and Technische Universität München, Munich, Germany.
Takeshi KimuraDepartment of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Pedro A LemosHospital Israelita Albert Einstein and Heart Institute (InCor) University of São Paulo Medical School, São Paulo, Brazil.
Renato D LopesDuke University Medical Center, The Duke Clinical Research Institute, Durham, NC, USA.
Roxana MehranIcahn School of Medicine at Mount Sinai, Cardiovascular Institute, New York, NY, USA.ORCID 0000-0002-5546-262X
Michelle L O'DonoghueTIMI Study Group, Brigham and Women's Hospital, Boston, MA, USA.
Sunil V RaoDuke University Medical Center, The Duke Clinical Research Institute, Durham, NC, USA.
Fabiana RolliniUniversity of Florida College of Medicine, Jacksonville, FL, USA.
Patrick W SerruysThe Lambe Institute for Translational Medicine and Curam, National University of Ireland Galway, Galway, Ireland.
Philippe G StegUniversité de Paris, INSERM U-1148, AP-HP, Hôpital Bichat, Paris, France.
Robert F StoreyDepartment of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.ORCID 0000-0002-6677-6229
Marco ValgimigliCardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano and Bern University Hospital, Bern, Switzerland.
Pascal VranckxDepartment of Cardiology and Critical Care Medicine, Jessaziekenhuis, Faculty of Medicine and Life Sciences, University of Hasselt, Hasselt, Belgium.
Hirotoshi WatanabeDepartment of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Stephan WindeckerDepartment of Cardiology, Bern University Hospital, Inselspital, Bern, Switzerland.
Dominick J AngiolilloUniversity of Florida College of Medicine, Jacksonville, FL, USA. dominick.angiolillo@jax.ufl.edu.ORCID 0000-0001-8451-2131
University of Florida · USBrigham and Women's Hospital · USCardiovascular Institute of the South · USClinical Research Institute · USInserm · FRKyoto University · JPBeth Israel Deaconess Medical Center · USDeutsches Herzzentrum München · DEEnte Ospedaliero Cantonale · CHJessa Hospital · BEOllscoil na Gaillimhe – University of Galway · IESamsung Medical Center · KRUniversidade de São Paulo · BRUniversity Hospital of Bern · CHUniversity of Catania · ITUniversity of Oklahoma Health Sciences Center · USUniversity of Sheffield · GB
Funding
No grant is acknowledged in the PubMed record.
Abstract
For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a platelet P2Y
Indexed as
Percutaneous Coronary InterventionAspirinDrug Therapy, CombinationDual Anti-Platelet TherapyHumansPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsTreatment OutcomeAspirinPlatelet Aggregation InhibitorsPurinergic P2Y Receptor Antagonists
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
NCT05681702ClinicalTrials.gov
NCT06588595ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.